Develops and markets nutrigenomic activators designed to influence gene expression. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
An average decline of 3% a year over the last 4 years — the most striking risk in this picture.
The market pays 15.3× for every dollar of annual profit — around what a business like this usually costs.
Against companies in its own sector, it looks cheaper than 85% of them.
Analysts' average target sits 3% below today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
The cash pile is strong; debt and other items pull the grade toward the middle.
The price looks reasonable next to what the company earns.
Clearly below the class average.
Clearly below the class average.
Growth: Sales growth trails the sector average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
An investor who bought at the very peak is down 76% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $14.9M in the vault; even if every debt were paid off, $5.1M would remain.
It pays out $0.19 per share each year — regular cash for whoever holds the stock.
Over the last 4 years, sales fell about 3% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The growth engine is running at low revs right now. Report-card grade: 9/100.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 29/100. For a turnaround signal, the stock first needs to close the gap with the market.
On our five-subject report card, LFVN sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: LFVN is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.